Journal Article10.1016/S0022-5347(01)61700-2
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
Anthony V. D'Amico,R. Whittington,S.B. Malkowicz,Daniel Schultz,Kenneth R. Blank,Gregory A. Broderick,John E. Tomaszewski,Andrew A. Renshaw,Irving D. Kaplan,Clair J. Beard,Alan J. Wein +10 more
TL;DR: Low-risk patients had estimates of 5-year PSA outcome after treatment with RP, RT, or implant with or without neoadjuvant androgen deprivation that were not statistically different, whereas intermediate- and high- risk patients treated with RP or RT did better then those treated by implant.
read more
About: This article is published in The Journal of Urology. The article was published on 01 Apr 1999. The article focuses on the topics: PSA Failure & Prostate cancer.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Clinical Outcomes of Dose-escalated Radiotherapy for Localised Prostate Cancer: A Single-institution Experience.
Katherine Meng,Keith Hsiu Chin Lim,Chia Ching Lee,David Chia,Kiat Huat Ooi,Yu Yang Soon,Jeremy Tey +6 more
TL;DR: Dose escalation to >74 Gy did not improve overall survival (OS) or freedom from biochemical failure (FFBF) but was associated with a higher rate of grade 3 or more rectal haemorrhage.
6
Subclassification of high-risk clinically organ-confined prostate cancer for early cancer-specific mortality after radical prostatectomy.
Takashi Kobayashi,Takahiro Kimura,Chunwoo Lee,Takahiro Inoue,Naoki Terada,Yuka Kono,Tomomi Kamba,Choung-Soo Kim,Shin Egawa,Osamu Ogawa +9 more
TL;DR: A modified D'Amico risk criteria for substratification of high-risk prostate cancer with regard to the prediction of biochemical recurrence, clinical progression-free survival or prostate cancer-specific mortality after radical prostatectomy is validated.
Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study.
Luke Witherspoon,Johnathan L. Lau,Rodney H. Breau,Christopher Knee,Michael Fung Kee Fung,Robin Morash,Ranjeeta Mallick,Ilias Cagiannos,Christopher Morash,Luke T. Lavallée +9 more
- 30 Apr 2018
TL;DR: Almost all patients have had clinically significant cancer in recent years, which suggests that overtreatment of prostate cancer has decreased and there has been a change in the tumour characteristics of patients who undergo prostatectomy in Eastern Ontario.
Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer
Wojciech A Cieślikowski,Piotr Milecki,Monika Świerczewska,Agnieszka Ida,Michał Kasperczak,Agnieszka Jankowiak,Michał Nowicki,Klaus Pantel,Catherine Alix-Panabières,Maciej Zabel,Andrzej Antczak,Joanna Budna-Tukan +11 more
TL;DR: In this paper , the baseline circulating tumor cell (CTCTC) count was used as a predictor of overall survival (OS) and metastasis-free survival (MFS) in patients with high-risk prostate cancer (PCa) during a follow-up period of at least 5 years.
Needle biopsy size and pathological Gleason Score diagnosis: No evidence for a link
TL;DR: Needle size does not affect the concordance between biopsy and pathological GS, and age, prostate-specific antigen, prostate volume and needle calibre were not independently associated with a higher risk of GS discordance.
References
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
28.6K
Results of Conservative Management of Clinically Localized Prostate Cancer
Gerald W. Chodak,Ronald A. Thisted,Glenn S. Gerber,Jan-Erik Johansson,Jan Adolfsson,George W. Jones,Geoff D. Chisholm,Boaz Moskovitz,Pinhas M. Livne,John J. Warner +9 more
TL;DR: The strategy of initial conservative management and delayed hormone therapy is a reasonable choice for some men with grade 1 or 2 clinically localized prostate cancer, particularly for those who have an average life expectancy of 10 years or less.
913
Prostate Specific Antigen Based Disease Control Following Ultrasound Guided sup 125 Iodine Implantation for Stage T1/T2 Prostatic Carcinoma
TL;DR: There is a high rate of clinical and chemical freedom from progression following 125I implantation for select patients with early stage prostatic carcinoma.
274
Related Papers (5)
Nicolas Mottet,Joaquim Bellmunt,Michel Bolla,Erik Briers,Marcus G. Cumberbatch,Maria De Santis,Nicola Fossati,Tobias Gross,Ann Henry,Steven Joniau,Thomas B. Lam,Thomas B. Lam,Malcolm David Mason,Vsevolod Matveev,Paul C. Moldovan,Roderick C.N. van den Bergh,Thomas Van den Broeck,Henk G. van der Poel,Theo H. van der Kwast,Olivier Rouvière,Ivo G. Schoots,Thomas Wiegel,Philip Cornford +22 more
Geert J.L.H. van Leenders,Theodorus van der Kwast,David J. Grignon,Andrew Evans,Glen Kristiansen,Charlotte F. Kweldam,Geert Litjens,Jesse K. McKenney,Jonathan Melamed,N. Mottet,Gladell P. Paner,Hemamali Samaratunga,Ivo G. Schoots,Jeffry P. Simko,Toyonori Tsuzuki,Murali Varma,Anne Y. Warren,Thomas M. Wheeler,Sean R. Williamson,Kenneth A. Iczkowski +19 more